Publication
Title
FTY720 combined with tacrolimus in de novo renal transplantation : 1-year, multicenter, open-label randomized study
Author
Institution/Organisation
FTY720 Phase II Transplant Study G
Abstract
Background. FTY720 (fingolimod), a novel immunomodulator, has demonstrated potential for prevention of acute rejection in combination with cyclosporine. Methods. This study evaluated FTY720 2.5 mg versus mycophenolate mofetil (MMF) in a combination regimen with standard tacrolimus and corticosteroids in de novo renal transplant recipients for the composite efficacy within 6 months of transplantation. Results. Incidence of treated biopsy-proven acute rejection was 22.9% with FTY720 and 18.5% with MMF. Increased incidence of macular oedema, transient decrease in heart rate and low rate of infections were seen in the FTY720 arm. Conclusion. FTY720 combined with tacrolimus and steroids did not show a significant therapeutic advantage over MMF for the prevention of acute rejection in de novo renal transplant recipients.
Language
English
Source (journal)
Nephrology, dialysis, transplantation. - Berlin
Publication
Berlin : 2011
ISSN
0931-0509
Volume/pages
26:11(2011), p. 3802-3805
ISI
000296350400060
Full text (Publisher's DOI)
Full text (open access)
UAntwerpen
Faculty/Department
Project info
Publication type
Subject
External links
Web of Science
Record
Identification
Creation 06.01.2015
Last edited 30.11.2017